Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line

Chemotherapy

Volumn 56, Issue 2, 2010, Pages 101-107

  Liu, Si Yuan ^a   Song, Shu Xia ^a   Lin, Liang ^a   Liu, Xing ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bax; Bcl 2; Cell cycle; Cyclin D1; Cyclin E; MG 63 cell line; Paclitaxel; PCNA; Pirarubicin

Indexed keywords

CYCLIN D1; CYCLIN E; CYCLINE; PACLITAXEL; PIRARUBICIN; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOSARCOMA; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 77950038755     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000305257     Document Type: Article

References (19)

1. Weis L: Common malignant bone tumors: Osteosarcoma; in Simon MA, Springfield D (eds): Surgery for Bone and Soft-Tissue Tumors. Philadelphia, Lippincott-Raven, 1997.
2. Mirra JM: Bone tumors: clinical, radiologic, and pathologic correlations. Philadelphia, Lea & Febiger, 1989.
3. Dorfman HD, Czerniak B: Osteosarcoma; in Dorfman HD, Czerniak B (eds): Bone Tumors. St. Louis, Mosby, 1998.
4. Sakamoto A, Iwamoto Y: Current status and perspectives regarding the treatment of osteo- sarcoma: chemotherapy. Rev Recent Clin Trials 2008; 3: 228-231.
5. Bhalla KN: Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22: 9075-9086.
6. Tamotsu S, Masayuki N, Hideyuki S, Naoto TU: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004; 64: 2502-2508.
7. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T: Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by antimicrotubule agents in human lung cancer. Am J Pathol 2003; 163: 1109-1116.
8. Chen JG, Horwitz SB: Differential mitotic responses to microtubule-stabilizing and destabilizing drugs. Cancer Res 2002; 62: 1935-1938.
9. Nagai K, Nagasawa K, Sadzuka Y, Tsujimoto M, Takara K, Ohnishi N, Yokoyama T, Fujimoto S: Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 2002; 49: 244-250.
10. Nagai K, Nagasawa K, Ishimoto A, Fujimoto S: Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 2003; 51: 512-518.
11. Lu KH, Lue KH, Chou MC, Chung JG: Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res 2005; 23: 988-994.
12. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K: Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother 2002; 36: 996-999.
13. Green H: Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics 2008; 9: 671-674.
14. Poirier VJ, Hershey AE, Burgess KE, Phillips B, Turek MM, Forrest LJ, Beaver L, Vail DM: Efficacy and toxicity of paclitaxel for the treatment of canine malignant tumors. J Vet Intern Med 2004; 18: 219-222.
15. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
16. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al: HMGB-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
17. Balcer-Kubiczek EK, Attarpour M, Jiang J, Kennedy AS, Suntharalingam M: Cytotoxicity of docetaxel (Taxotere- ) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy 2006; 52: 231-240.
18. Nakashima H, Nishida Y, Sugiura H, Katagiri H, Yonekawa M, Yamada Y, Iwata H, Nagasaka T, Ishiguro N: Telomerase, p53 and PCNA activity in osteosarcoma. Eur J Surg Oncol 2003; 29: 564-567.
19. Eskiocak U, İşeri, OD Kars MD, Biçer A, Gunduz U: Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells. Chemotherapy 2008; 54: 209-216.